Research on Parkinson's disease and its treatment. Covers mitochondrial protection, genetic progression markers, antibody therapies, and disease costs.
A new study found that a molecular compound called CLR01 improves balance and coordination in mice with early-stage Parkinson's disease. CLR01 reduces the amount of toxic alpha-synuclein protein in the brain, which is thought to contribute to the development of the disorder.
A large study published in Neurology found that consuming at least three servings of low-fat dairy per day is associated with a greater risk of developing Parkinson's disease compared to less than one serving. The study also found an increased risk for those drinking more than one serving of low-fat or skim milk per day.
Researchers at the University of Central Florida have developed a new screening tool for Parkinson's disease using CRISPR technology. The tool allows scientists to monitor brain protein alpha-synuclein levels, which can help identify potential treatments.
Researchers at OIST Graduate University have identified the precise toxic mechanism of alpha-synuclein, a key causative agent in Parkinson's development. The protein inhibits vesicle endocytosis, critical for neurotransmission, leading to its devastating effects on motor control and cognitive function.
Research in npj Parkinson’s Disease suggests a link between influenza virus infection and the development of Parkinson’s disease. Mice infected with H1N1 influenza were more susceptible to chemical toxins that trigger Parkinson’s symptoms, but vaccination or antiviral medications mitigated this effect.
Researchers found that abnormal proteins in Alzheimer's, Parkinson's, and Huntington's diseases cause the same type of vesicle damage, potentially leading to effective treatments for multiple neurodegenerative diseases.
Researchers have pinpointed a common protein abnormality, SOD1 fingerprint, in Parkinson's disease brains, suggesting a new target for therapies that improved ALS outcomes. The finding may lead to substantial improvements in motor function and survival time for Parkinson's patients.
Researchers identified neural circuits behind sensory deficits in Parkinson's disease by studying mice with dopamine-depleted brains. The study found that treating mice with L-DOPA restored their ability to distinguish between left and right whiskers, offering new avenues for earlier diagnosis.
Researchers identified biomarkers that correlate with cognitive decline in early Parkinson's disease, including dopamine deficiency, brain atrophy, and genetic mutations. The study may improve clinical care and develop new treatments for cognitive impairments in Parkinson's disease.
Researchers identified brain scans, genetic tests, and CSF analysis as predictive biomarkers for Parkinson's disease-related cognitive decline. Biomarkers associated with dopamine deficiency, beta-amyloid protein, and single nucleotide polymorphisms were found to correlate with cognitive impairment in newly diagnosed patients.
A study found significant racial disparities in neurologic healthcare access and utilization in the US. Black and Hispanic individuals had lower rates of outpatient neurologist visits and more hospital emergency department visits compared to white individuals.
Researchers at MIT have developed a new brain implant design that uses thin fibers to deliver drugs or electrical stimulation with less damage to the brain. The design reduces scarring, potentially allowing devices to remain in the brain for much longer.
A study published in JAMA Neurology found that patients with Parkinson disease and dementia with Lewy bodies died approximately two years earlier than the general population. The highest risk of death was seen among those with multiple system atrophy with parkinsonism, highlighting the need for tailored care and management strategies.
A Mayo Clinic study found that patients with Parkinson's disease, Lewy body dementia, and related conditions died 2-6 years earlier than the general population. The study used data from 1991 to 2010 and compared 461 patients with these diseases to 452 patients in the general population.
Researchers at Carnegie Mellon University have identified two groups of neurons that can be targeted with optogenetics to alleviate Parkinson's disease symptoms. By activating these cells, they were able to restore movement for at least four hours, significantly longer than current treatments.
Researchers have discovered that doxycycline can reduce α-synuclein aggregation and improve symptoms in animal models of Parkinson's disease. This could lead to a potential treatment option for the degenerative condition.
A new special collection in Disease Models & Mechanisms (DMM) explores the intersection of models and mechanisms to therapies for neurodegenerative disorders. The collection includes articles on induced pluripotent stem cell models, antisense oligonucleotide therapy for spinal muscular atrophy, and more.
University at Buffalo researchers have successfully reproduced Parkinson's brain oscillations in a petri dish using stem cells. This breakthrough could speed up the development of new treatments and even lead to a cure for Parkinson's disease.
A recent study found that people who had a truncal vagotomy at least five years earlier were 40% less likely to develop Parkinson's disease than those who did not have the surgery. The study suggests that the gut may play a role in the development of Parkinson's disease, which often involves gastrointestinal problems.
A research team at DGIST has discovered a candidate substance that can prevent and potentially cure Parkinson's disease by inducing the expression of the parkin protein. Cortisol, a stress hormone, promotes the production of this protein, which protects dopaminergic neurons from death.
A new study on UHT milk has found a link between protein clusters and age-related diseases like Alzheimer
A new study found that the old drug apomorphine can significantly reduce 'off' times in patients with advanced Parkinson's disease, improving their quality of life. The treatment was effective even after just one week and was well-tolerated.
Researchers at the University of Luxembourg have successfully grown brain-like cultures from human stem cells, mirroring the structure and function of the midbrain. This breakthrough allows for the study of Parkinson's disease mechanisms and potential treatments, as well as reducing animal testing in brain research.
Researchers found UM-Palmitoylethanolamide to slow down Parkinson's disease progression and disability, improving non-motor and motor aspects of daily living. The study used ultra-micronized palmitoylethanolamide as an add-on therapy in advanced PD patients, with significant reductions in symptoms.
Researchers have developed a way to deliver drugs to specific types of neurons in the brain, allowing for more precise study and treatment of neurological diseases. The new method, DART, reveals how movement difficulties in Parkinson's Disease are controlled by the AMPA receptor, offering a new approach to treating the disease.
A research team from the University of Freiburg has developed a new method to create microprobes that can grow into neural tissue without causing inflammation. These probes can deliver strong signals even after twelve weeks, opening up new possibilities for diagnoses and treatments for conditions like Parkinson's.
A recent study published in Neurology found that people with hepatitis B are 76% more likely to develop Parkinson's disease than those without the virus. Those with hepatitis C have a 51% increased risk. The research linked both viruses to an increased risk of Parkinson's disease, contradicting previous findings on hepatitis B.
A team of chemists from Konstanz University has made a significant discovery about the effects of selective mutations on the alpha-synuclein protein. By applying magnetic probes to the protein, they found that these changes disturb the binding of alpha-synuclein to membranes.
Researchers propose a new approach to treating Parkinson's disease by identifying specific symptoms and molecular features of individual patients. By developing biomarkers and tailoring therapies to distinct patient subtypes, scientists aim to improve treatment outcomes and potentially slow or cure the disease.
A University of Leicester study found that folinic acid can protect neurons in fruit flies with Parkinson's disease, offering potential hope for people with early-onset forms of the condition. The researchers believe that supplementing folinic acid could be a faster and more effective treatment option than developing new drugs.
Researchers at Salk Institute find that changing dopamine levels can alter upcoming choices, suggesting new avenues for treating Parkinson's and OCD. The study uses advanced techniques to measure dopamine concentration in mice brains, revealing a tight association between brain chemistry and decision-making.
Researchers discovered a connection between the SV2C protein and dopamine release in the brain, suggesting that drug therapies targeting SV2C may be beneficial for PD patients. The study found altered SV2C levels only in PD brains among patients with various neurodegenerative diseases.
Research finds a strong association between Parkinson's disease and stroke, with a higher incidence of ischemic stroke among those with Parkinson's. This link is similar to that between stroke and Alzheimer's disease.
Researchers at the University of Leicester have discovered a genetic 'switch' called ATF4 that plays a key role in Parkinson's disease. By targeting this gene, they hope to develop tailored interventions that can prevent or delay neuronal loss.
Researchers are exploring a new infusion therapy that could help smooth out movement for patients with Parkinson's by providing constant levodopa levels and stimulating dopamine receptors. The therapy aims to reduce off-time and increase on-time movement, improving overall quality of life.
Researchers identified cardiolipin, a mitochondrial lipid, as a potential target for reducing Parkinson's symptoms. Blocking the FASN protein increased cardiolipin levels and improved mitochondrial function, providing new insights into the disease.
A Yale University review of animal studies found that therapies successful in animals fail in humans due to early intervention timing and narrow study designs. The researchers highlight the need for more accurate translation from animal models to human trials.
A new study suggests a simple blood test can differentiate between Parkinson's disease and atypical parkinsonism disorders as accurately as a spinal fluid test. Researchers found that concentrations of neurofilament light chain protein in the blood can discriminate between these diseases.
Researchers discovered two distinct neural networks controlling the balance between speed and accuracy when making decisions. The subthalamic nucleus region plays a key role in this process, with one network requiring more information for accurate decisions and another lowering the threshold for quick choices.
A recent study published in Archives of Physical Medicine and Rehabilitation found that hand-grip strength is a reliable indicator of physical function decline in Parkinson's patients. The researchers used a portable monitoring device to measure muscle activity, showing that the test was conclusive and easy to administer.
A study found that two problem proteins known to cause Parkinson's disease are chemically linked, suggesting a common target for a single drug. Reducing one protein leads to an increase in the other, which can be mitigated by a treatment targeting the link.
Research at Lund University found that both neural pathways in the striatum, called direct and indirect pathway, work together to control movements, not independently. This discovery may lead to new treatments for movement disorders like Parkinson's disease by targeting both pathways.
Researchers have shed light on the relationship between misfolded alpha-synuclein protein and Parkinson's disease, identifying key genes and cellular processes involved. The study provides new insights into the underlying mechanisms of synucleinopathies, paving the way for developing patient-specific treatments.
A Norwegian study from the University of Bergen has identified key mechanisms behind Parkinson's disease, which may lead to future treatments. The research suggests that mitochondrial DNA damage is a primary cause of the disease, and that healthy brain cells can compensate for this damage by producing more DNA.
A synthesized steroid called squalamine has been shown to prevent the buildup of a lethal protein implicated in neurodegenerative diseases like Parkinson's. In an animal model, squalamine reduced the toxicity of alpha-synuclein clumps and protected healthy human neuronal cells from damage.
Researchers found that squalamine inhibits the early formation of toxic alpha-synuclein aggregates and suppresses their toxicity. The compound was tested in cell cultures, animal models, and human neuronal cells, showing promising results.
Researchers found that increasing niacin levels boosts NAD compound for energy generation and DNA repair, potentially protecting against Parkinson's. The study suggests repurposing cancer drugs to protect faulty mitochondria in Parkinson's disease.
Researchers found that chemicals extracted from prickly pear and brown seaweed improve cellular and animal models of neurodegenerative proteinopathies. The study suggests these substances may target pathways affected by multiple neurodegenerative conditions.
A laboratory study found that alpha-synuclein, a protein involved in Parkinson's disease, can travel from the brain to the stomach via specific nerve pathways. The protein was detected in gastric nerve terminals six months after its initial midbrain expression.
Duke University researchers have developed a new approach to deep brain stimulation that reduces energy consumption by up to 75% without compromising treatment efficacy. The algorithm uses computational evolution to design tailored patterns for individual patients, leading to improved symptoms and reduced battery replacement procedures.
A study of over 6.5 million Ontario residents found that those living within 50 meters of high-traffic roads had a seven percent higher likelihood of developing dementia compared to those further away. The risk increased with proximity, but not for Parkinson's disease or multiple sclerosis.
Richard Myers is investigating the Cyclin G-associated kinase (GAK) gene and its role in Parkinson's disease. His research aims to understand how increasing GAK levels may prevent cell death in PD.
Welders exposed to low levels of manganese exhibit neurological symptoms similar to Parkinson's disease, including slow movement and difficulty speaking. Current OSHA safety standards may not protect workers from the dangers of welding fumes.
A study published in Neurology found that welders who work with manganese fumes are more likely to develop Parkinson's-like symptoms. The researchers analyzed data from 886 workers and found that cumulative exposure to manganese was associated with a yearly increase in movement problems.
Researchers have found that activating the protein Nrf2 can restore normal levels of disease-causing proteins in cells, preventing cell death. In models of Parkinson's and Huntington's diseases, Nrf2 was shown to protect cells against the disease better than any other treatment.
A new study reveals that brain stimulation can improve timing abilities in mice lacking dopamine, a key player in Parkinson's disease. The breakthrough finding suggests that targeted brain stimulation could be used to treat cognitive problems caused by PD and possibly other conditions.
Researchers at the University of Helsinki have successfully corrected Parkinson's disease motor symptoms in mice using a PREP blocker treatment. The treatment, which blocks the formation of alpha-synuclein aggregates, restored motor skills and cleared brain accumulations within two weeks.
Researchers found significant alterations in brain networks of PD patients with mild cognitive impairment, indicating complex structural brain network disruption rather than individual white matter degeneration. The study suggests using MRI to monitor the disease and predict cognitive complications.
Researchers have developed a diabetes drug that slows experimental Parkinson's disease progression by regulating mitochondrial function and reducing inflammation. Human trials are set to begin next year, offering hope for the first treatment to target the underlying disease.
Researchers detect misfolded alpha-synuclein aggregates in cerebrospinal fluid to diagnose Parkinson's disease. The Protein Misfolding Cyclic Amplification technology detects small amounts of the protein, correlating with disease severity.